PCAS: NET SALES AS OF DECEMBER 31, 2021
January 27 2022 - 12:00PM
PCAS: NET SALES AS OF DECEMBER 31, 2021
Ecully, January 27, 2022
NET SALES AS OF DECEMBER 31,
2021
PCAS (Euronext Paris: PCA), a
specialist in developing and producing complex molecules for life
sciences and innovative technologies, has announced the publication
of its consolidated net sales as of December 31, 2021.
The PCAS Group has generated consolidated net
sales of €187.0 million as of December 31, 2021, a 3.7%
decrease compared to the same period during the previous financial
year (-2.6% at constant exchange rates).
|
In millions of euros |
|
2021 |
|
2020 |
|
% change |
|
2021 At a constant exchange rate |
|
% change |
|
|
|
|
|
|
|
|
|
|
|
|
| Net
sales as of 31 december |
|
187.0 |
|
194.1 |
|
-3.7% |
|
189.1 |
|
-2.6% |
| Pharmaceutical
Synthesis |
|
119.6 |
|
135.2 |
|
-11.5% |
|
121.0 |
|
-10.5% |
|
Fine Specialty Chemicals |
|
67.4 |
|
58.9 |
|
14.4% |
|
68.1 |
|
15.7% |
Pharmaceutical Synthesis
The Pharmaceutical Synthesis business generated
sales of €119.6 million, a 11.5% decrease compared to 2020 (a 10.5%
decrease at a constant exchange rate). The strong decrease in sales
of hand sanitizer, compared to peak consumption in 2020, as well as
lower volumes on several other products, particularly from the
Limay site, could not be compensated as initially planned by the
increase in volumes of Estetrol, due to delays in the production of
this molecule manufactured for Mithra in the new highly active
pharmaceutical drug production workshop located in
Villeneuve-La-Garenne.
Fine Specialty Chemicals
Net sales of Fine Specialty Chemicals totaled
€67.4 million, a 14.4% increase compared to 2020 (+15.7% at a
constant exchange rate). All activities experienced strong sales
growth, with particularly strong demand in Electronics and
Lubricants, and a good recovery in Cosmetics. Supply and logistics
difficulties have been closely monitored and had therefore a
limited impact on net sales. Demand for new projects continues to
show a good dynamics.
Outlook
The publication of the PCAS Group 2021 results
is scheduled for February 24.
The 2021 results will show a substantial net
loss mainly due to the delay in sales of Estetrol, and overall a
level of net sales which remains insufficient to cover the
additional fixed costs incurred at several production sites in
recent years in order to improve the quality of manufacturing
processes.
All PCAS Group teams, with the support of its
shareholder Seqens, are fully involved in improving the Group's
results.
NEXT FINANCIAL DISCLOSURE:
2021 Results, February 24, 2022
ABOUT PCAS
PCAS specializes in the development and
production of complex molecules for life sciences and innovative
technologies. With about 10% of its net sales earmarked for R&D
and a large international footprint, PCAS is the preferred
industrial partner for market-leading major global groups. Boasting
especially high standards, the company offers a growing range of
proprietary products and solutions in leading-edge segments. PCAS
generated net sales of €187.0 million in 2021 and employs nearly
1100 people in six countries.To find out more about PCAS:
www.pcas.com
|
PCAS |
NewCap |
|
Pierre Luzeau / Eric Moissenot |
Emmanuel Huynh / Louis-Victor Delouvrier Financial
communication and investor relations |
|
Tel.: +33 1 69 79 60 00www.pcas.com |
Tel.: +33 1 44 71 98 53pcas@newcap.eu |
| |
|
- PCAS_PR_2021_activity_ENG
Pcas (LSE:0NF7)
Historical Stock Chart
From Jul 2024 to Aug 2024
Pcas (LSE:0NF7)
Historical Stock Chart
From Aug 2023 to Aug 2024
